Infants aged <8 months born during or entering their first RSV season are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥ 5 kg).
Children aged 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of nirsevimab (200 mg).
Adults 60 years of age and older may receive a single dose of RSV vaccines, using shared clinical decision-making.
Talk with your doctor or care team about vaccine options right for you.
